Artivion, Inc. (NYSE:AORT) Given Average Recommendation of “Moderate Buy” by Brokerages

Artivion, Inc. (NYSE:AORT) has earned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $44.8333.

AORT has been the topic of several recent research reports. Needham & Company LLC restated a “buy” rating and set a $44.00 target price on shares of Artivion in a research report on Monday, July 20th. Canaccord Genuity Group boosted their price objective on Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Citizens Jmp lowered their price objective on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research note on Friday, May 8th. Stifel Nicolaus set a $45.00 price objective on Artivion in a research note on Monday, June 1st. Finally, Citigroup reiterated a “market outperform” rating on shares of Artivion in a report on Tuesday, July 21st.

Artivion Trading Down 3.6%

AORT stock opened at $27.07 on Tuesday. The firm has a fifty day moving average price of $25.20 and a 200 day moving average price of $29.96. Artivion has a fifty-two week low of $19.16 and a fifty-two week high of $48.25. The firm has a market cap of $1.32 billion, a PE ratio of -386.66 and a beta of 1.24. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.13 EPS for the quarter. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. The business had revenue of $125.76 million during the quarter, compared to analyst estimates of $119.99 million. Sell-side analysts anticipate that Artivion will post 0.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Artivion news, SVP Andrew M. Green sold 44,001 shares of Artivion stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the transaction, the senior vice president directly owned 60,259 shares of the company’s stock, valued at $1,247,361.30. The trade was a 42.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO James P. Mackin sold 70,000 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the transaction, the chief executive officer owned 877,275 shares in the company, valued at $25,397,111.25. This trade represents a 7.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 114,978 shares of company stock worth $2,965,155 over the last three months. 6.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Artivion

Several hedge funds have recently added to or reduced their stakes in AORT. California State Teachers Retirement System raised its position in Artivion by 2,086.7% in the 2nd quarter. California State Teachers Retirement System now owns 1,119,860 shares of the company’s stock worth $25,163,000 after purchasing an additional 1,068,647 shares during the period. Susquehanna International Group LLP grew its stake in shares of Artivion by 584.1% during the second quarter. Susquehanna International Group LLP now owns 102,531 shares of the company’s stock valued at $2,304,000 after buying an additional 87,544 shares during the last quarter. Van ECK Associates Corp raised its holdings in shares of Artivion by 65.9% in the second quarter. Van ECK Associates Corp now owns 10,749 shares of the company’s stock worth $242,000 after buying an additional 4,269 shares during the period. Wellington Management Group LLP raised its holdings in shares of Artivion by 9.0% in the second quarter. Wellington Management Group LLP now owns 1,260,279 shares of the company’s stock worth $28,318,000 after buying an additional 103,592 shares during the period. Finally, Corient Private Wealth LP bought a new stake in shares of Artivion during the 2nd quarter worth approximately $3,579,000. 86.37% of the stock is currently owned by institutional investors.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.